Skip to main content
SpringerLink
Log in

Circulating Biomarkers for Esophageal Squamous Cell Carcinoma

  • Chapter
  • First Online:
New Advances on Disease Biomarkers and Molecular Targets in Biomedicine

  • 998 Accesses

Abstract

Esophageal cancer is the eighth most common cancer worldwide and esophageal squamous cell carcinoma (ESCC) is the predominant type in Asia. Surgical resection of the tumor is the mainstay treatment for ESCC. Recent advances in neoadjuvant or adjuvant chemotherapy/chemoradiotherapy for treatment of ESCC have significantly improved prognosis. Despite these advancements, survival of some patients still remains poor in particular for those diagnosed at a late stage. In view of the asymptomatic nature of early ESCC and the limitations of currently used diagnostic methods, there is a pressing need to identify circulatory biomarkers to allow noninvasive and early detection of ESCC. In this chapter, we summarize circulating cancer biomarkers including circulatory proteins, microRNAs, and tumor cells that are found to have elevated level in serum and plasma of ESCC patients when compared to healthy subjects. These biomarkers could help improve the diagnostic efficiency of ESCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349(23):2241–2252

    PubMed  CAS  Google Scholar 

  2. Stewart BW, Kleihues P, International Agency for Research on Cancer (2003) World cancer report. IARC Press, Lyon, p 351

    Google Scholar 

  3. Cameron AJ, Lomboy CT, Pera M, Carpenter HA (1995) Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology 109(5):1541–1546

    PubMed  CAS  Google Scholar 

  4. Choi SY, Kahyo H (1991) Effect of cigarette smoking and alcohol consumption in the aetiology of cancer of the oral cavity, pharynx and larynx. Int J Epidemiol 20(4):878–885

    PubMed  CAS  Google Scholar 

  5. Adami HO, McLaughlin JK, Hsing AW, Wolk A, Ekbom A, Holmberg L, Persson I (1992) Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control 3(5):419–425

    PubMed  CAS  Google Scholar 

  6. Ghadirian P, Ekoe JM, Thouez JP (1992) Food habits and esophageal cancer: an overview. Cancer Detect Prev 16(3):163–168

    PubMed  CAS  Google Scholar 

  7. Shuker DE, Bartsch H (1994) DNA adducts of nitrosamines. IARC Sci Publ 125:73–89

    PubMed  CAS  Google Scholar 

  8. Jakszyn P, Gonzalez CA (2006) Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence. World J Gastroenterol 12(27):4296–4303

    PubMed  CAS  Google Scholar 

  9. Earlam R, Cunha-Melo JR (1980) Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 67(6):381–390

    PubMed  CAS  Google Scholar 

  10. Anderson LL, Lad TE (1982) Autopsy findings in squamous-cell carcinoma of the esophagus. Cancer 50(8):1587–1590

    PubMed  CAS  Google Scholar 

  11. Holscher AH, Schneider PM, Gutschow C, Schroder W (2007) Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg 245(2):241–246

    PubMed  Google Scholar 

  12. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR (2001) Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 234(4):520–530

    PubMed  CAS  Google Scholar 

  13. Peyre CG, DeMeester SR, Rizzetto C, Bansal N, Tang AL, Ayazi S, Leers JM, Lipham JC, Hagen JA, DeMeester TR (2007) Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia. Ann Surg 246(4):665–671

    PubMed  Google Scholar 

  14. Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8(6):545–553

    PubMed  Google Scholar 

  15. Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger M (2007) Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg 246(4):624–628

    PubMed  Google Scholar 

  16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66

    PubMed  Google Scholar 

  17. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83(1):18–29

    PubMed  CAS  Google Scholar 

  18. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10(8):789–799

    PubMed  CAS  Google Scholar 

  19. Shibagaki I, Tanaka H, Shimada Y, Wagata T, Ikenaga M, Imamura M, Ishizaki K (1995) p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin Cancer Res 1(7):769–773

    PubMed  CAS  Google Scholar 

  20. Li X, Lu JY, Zhao LQ, Wang XQ, Liu GL, Liu Z, Zhou CN, Wu M, Liu ZH (2003) Overexpression of ETS2 in human esophageal squamous cell carcinoma. World J Gastroenterol 9(2):205–208

    PubMed  Google Scholar 

  21. Mathew R, Arora S, Khanna R, Mathur M, Shukla NK, Ralhan R (2002) Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur J Cancer 38(6):832–841

    PubMed  CAS  Google Scholar 

  22. Mathew R, Arora S, Khanna R, Shukla NK, Mathur M, Ralhan R (2001) Alterations in cyclin D1 expression in esophageal squamous cell carcinoma in the Indian population. J Cancer Res Clin Oncol 127(4):251–257

    PubMed  CAS  Google Scholar 

  23. Busatto G, Shiao YH, Parenti AR, Baffa R, Ruol A, Plebani M, Rugge M (1998) p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. Mol Pathol 51(2):80–84

    PubMed  CAS  Google Scholar 

  24. Parenti AR, Rugge M, Shiao YH, Ruol A, Ancona E, Bozzola L, Ninfo V (1997) bcl-2 and p53 immunophenotypes in pre-invasive, early and advanced oesophageal squamous cancer. Histopathology 31(5):430–435

    PubMed  CAS  Google Scholar 

  25. Liu Y, Wang HX, Lu N, Mao YS, Liu F, Wang Y, Zhang HR, Wang K, Wu M, Zhao XH (2003) Translocation of annexin I from cellular membrane to the nuclear membrane in human esophageal squamous cell carcinoma. World J Gastroenterol 9(4):645–649

    PubMed  CAS  Google Scholar 

  26. Zhu ML, Shi TY, Hu HC, He J, Wang M, Jin L, Yang YJ, Wang JC, Sun MH, Chen H, Zhao KL, Zhang Z, Chen HQ, Xiang JQ, Wei QY (2012) Polymorphisms in the ERCC5 gene and risk of esophageal squamous cell carcinoma (ESCC) in Eastern Chinese populations. PLoS One 7(7):e41500

    PubMed  CAS  Google Scholar 

  27. Zhai XD, Mo YN, Xue XQ, Zhao GS, Gao LB, Ai HW, Ye Y (2009) XRCC1 codon 280 and ERCC2 codon 751 polymorphisms and risk of esophageal squamous cell carcinoma in a Chinese population. Bull Cancer 96(10):E61–E65

    PubMed  Google Scholar 

  28. Dai L, Wang K, Zhang J, Lv Q, Wu X, Wang Y (2009) XRCC1 gene polymorphisms and esophageal squamous cell carcinoma risk in Chinese population: a meta-analysis of case-control studies. Int J Cancer 125(5):1102–1109

    PubMed  CAS  Google Scholar 

  29. Yu HP, Zhang XY, Wang XL, Shi LY, Li YY, Li F, Su YH, Wang YJ, Lu B, Sun X, Lu WH, Xu SQ (2004) DNA repair gene XRCC1 polymorphisms, smoking, and esophageal cancer risk. Cancer Detect Prev 28(3):194–199

    PubMed  CAS  Google Scholar 

  30. Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB (2004) Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res 64(5):1611–1620

    PubMed  CAS  Google Scholar 

  31. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, Qin YR, Guan XY (2012) MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 61(1):33–42

    PubMed  CAS  Google Scholar 

  32. Liu R, Liao J, Yang M, Sheng J, Yang H, Wang Y, Pan E, Guo W, Pu Y, Kim SJ, Yin L (2012) The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One 7(3):e33987

    PubMed  CAS  Google Scholar 

  33. Fujiwara S, Noguchi T, Takeno S, Kimura Y, Fumoto S, Kawahara K (2008) Hypermethylation of p16 gene promoter correlates with loss of p16 expression that results in poorer prognosis in esophageal squamous cell carcinomas. Dis Esophagus 21(2):125–131

    PubMed  CAS  Google Scholar 

  34. Seregni E, Coli A, Mazzucca N (2004) Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 31(Suppl 1):S15–S22

    PubMed  Google Scholar 

  35. Duk JM, Groenier KH, de Bruijn HW, Hollema H, ten Hoor KA, van der Zee AG, Aalders JG (1996) Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 14(1):111–118

    PubMed  CAS  Google Scholar 

  36. Holdenrieder S, Stieber P, Liska V, Treska V, Topolcan O, Dreslerova J, Matejka VM, Finek J, Holubec L (2012) Cytokeratin serum biomarkers in patients with colorectal cancer. Anticancer Res 32(5):1971–1976

    PubMed  CAS  Google Scholar 

  37. Molina R, Torres MD, Moragas M, Perez-Villa J, Filella X, Jo J, Farrus B, Gimenez N, Traserra J, Ballesta AM (1996) Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. Tumour Biol 17(2):81–89

    PubMed  CAS  Google Scholar 

  38. Tufman A, Huber RM (2010) Biological markers in lung cancer: a clinician’s perspective. Cancer Biomark 6(3–4):123–135

    PubMed  Google Scholar 

  39. Gold P, Freedman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439–462

    PubMed  CAS  Google Scholar 

  40. Lin DC, Du XL, Wang MR (2009) Protein alterations in ESCC and clinical implications: a review. Dis Esophagus 22(1):9–20

    PubMed  Google Scholar 

  41. Evans JT, Mittelman A, Chu M, Holyoke ED (1978) Pre- and postoperative uses of CEA. Cancer 42(3 Suppl):1419–1421

    PubMed  CAS  Google Scholar 

  42. Clark GW, Ireland AP, Hagen JA, Collard JM, Peters JH, DeMeester TR (1995) Carcinoembryonic antigen measurements in the management of esophageal cancer: an indicator of subclinical recurrence. Am J Surg 170(6):597–600

    PubMed  CAS  Google Scholar 

  43. Mealy K, Feely J, Reid I, McSweeney J, Walsh T, Hennessy TP (1996) Tumour marker detection in oesophageal carcinoma. Eur J Surg Oncol 22(5):505–507

    PubMed  CAS  Google Scholar 

  44. Munck-Wikland E, Kuylenstierna R, Wahren B, Lindholm J, Haglund S (1988) Tumor markers carcinoembryonic antigen, CA 50, and CA 19–9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer 62(11):2281–2286

    PubMed  CAS  Google Scholar 

  45. Kato H, Morioka H, Tsutsui H, Aramaki S, Torigoe T (1982) Value of tumor-antigen (TA-4) of squamous cell carcinoma in predicting the extent of cervical cancer. Cancer 50(7):1294–1296

    PubMed  CAS  Google Scholar 

  46. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J, Viladiu P (2003) Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24(4):209–218

    PubMed  CAS  Google Scholar 

  47. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H, Ochiai T (2003) Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 133(5):486–494

    PubMed  Google Scholar 

  48. Mino N, Iio A, Hamamoto K (1988) Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs. Cancer 62(4):730–734

    PubMed  CAS  Google Scholar 

  49. Bolger BS, Dabbas M, Lopes A, Monaghan JM (1997) Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol 65(2):309–313

    PubMed  CAS  Google Scholar 

  50. Lin H, ChangChien CC, Huang EY, Eng HL, Huang CC (2000) The role of radical surgery followed by adjuvant therapy for high-risk early-stage cervical carcinoma patients with pelvic lymph node metastasis. Eur J Obstet Gynecol Reprod Biol 93(1):85–90

    PubMed  CAS  Google Scholar 

  51. Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, Kadomatsu K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai T (2003) Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 94(7):628–632

    PubMed  CAS  Google Scholar 

  52. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31(1):11–24

    PubMed  CAS  Google Scholar 

  53. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, Meier W, Fateh-Moghadam A (1993) CYFRA 21-1. A new marker in lung cancer. Cancer 72(3):707–713

    PubMed  CAS  Google Scholar 

  54. Ferdeghini M, Gadducci A, Annicchiarico C, Prontera C, Malagnino G, Castellani C, Facchini V, Bianchi R (1993) Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. Anticancer Res 13(5C):1841–1844

    PubMed  CAS  Google Scholar 

  55. Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M, Gruener N (1995) Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 121(2):177–181

    PubMed  CAS  Google Scholar 

  56. Nakata B, Chung YS, Kato Y, Ogawa M, Ogawa Y, Inui A, Maeda K, Sawada T, Sowa M (1996) Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer 73(12):1529–1532

    PubMed  CAS  Google Scholar 

  57. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T (1997) CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 79(9):1647–1655

    PubMed  CAS  Google Scholar 

  58. Moll R, Krepler R, Franke WW (1983) Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation 23(3):256–269

    PubMed  CAS  Google Scholar 

  59. Wollenberg B, Ollesch A, Maag K, Funke I, Wilmes E (1994) Micrometastases in bone marrow of patients with cancers in the head and neck area. Laryngorhinootologie 73(2):88–93

    PubMed  CAS  Google Scholar 

  60. Kawaguchi H, Ohno S, Miyazaki M, Hashimoto K, Egashira A, Saeki H, Watanabe M, Sugimachi K (2000) CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer 89(7):1413–1417

    PubMed  CAS  Google Scholar 

  61. Yi Y, Li B, Wang Z, Sun H, Gong H, Zhang Z (2009) CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers 14(7):480–485

    PubMed  CAS  Google Scholar 

  62. Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S (1998) CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 11(1):35–39

    PubMed  CAS  Google Scholar 

  63. Quillien V, Raoul JL, Laurent JF, Meunier B, Le Prise E (1998) Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma. Oncol Rep 5(6):1561–1565

    PubMed  CAS  Google Scholar 

  64. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S (1984) Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J 3(13):3257–3262

    PubMed  CAS  Google Scholar 

  65. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM (1986) Localization of gene for human p53 tumour antigen to band 17p13. Nature 320(6057):84–85

    PubMed  CAS  Google Scholar 

  66. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252(5013): 1708–1711

    PubMed  CAS  Google Scholar 

  67. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eschwege F, Soussi T (1996) Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 88(17):1228–1233

    PubMed  CAS  Google Scholar 

  68. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52(22):6380–6384

    PubMed  CAS  Google Scholar 

  69. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58(4):480–487

    PubMed  CAS  Google Scholar 

  70. Crawford LV, Pim DC, Bulbrook RD (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30(4):403–408

    PubMed  CAS  Google Scholar 

  71. Soussi T (2000) p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60(7):1777–1788

    PubMed  CAS  Google Scholar 

  72. Gaur D, Arora S, Mathur M, Nath N, Chattopadhaya TK, Ralhan R (1997) High prevalence of p53 gene alterations and protein overexpression in human esophageal cancer: correlation with dietary risk factors in India. Clin Cancer Res 3(11):2129–2136

    PubMed  CAS  Google Scholar 

  73. Ralhan R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M (2000) Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 85(6):791–795

    PubMed  CAS  Google Scholar 

  74. Takahashi K, Miyashita M, Nomura T, Makino H, Futami R, Kashiwabara M, Katsuta M, Tajiri T (2007) Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus 20(2):117–122

    PubMed  CAS  Google Scholar 

  75. Elahi MM, Everson NW (2004) Prognosis of colorectal cancer patients with elevated endothelin-1 concentrations. Asian J Surg 27(1):4–9

    PubMed  Google Scholar 

  76. Hemsen A, Ahlborg G, Ottosson-Seeberger A, Lundberg JM (1995) Metabolism of big endothelin-1 (1–38) and (22–38) in the human circulation in relation to production of endothelin-1 (1–21). Regul Pept 55(3):287–297

    PubMed  CAS  Google Scholar 

  77. Wulfing P, Kersting C, Tio J, Fischer RJ, Wulfing C, Poremba C, Diallo R, Bocker W, Kiesel L (2004) Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 10(7):2393–2400

    PubMed  Google Scholar 

  78. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A (2002) Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 277(31):27850–27855

    PubMed  CAS  Google Scholar 

  79. Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R, Bagnato A (2000) Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 157(5):1703–1711

    PubMed  CAS  Google Scholar 

  80. Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosano L, Trisciuoglio D, Spinella F, Bagnato A (2002) Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 61(3):524–532

    PubMed  Google Scholar 

  81. Rosano L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A (2001) Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61(22):8340–8346

    PubMed  CAS  Google Scholar 

  82. Jiao W, Xu J, Zheng J, Shen Y, Lin L, Li J (2008) Elevation of circulating big endothelin-1: an independent prognostic factor for tumor recurrence and survival in patients with esophageal squamous cell carcinoma. BMC Cancer 8:334

    PubMed  Google Scholar 

  83. Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, Kraus MH, Aaronson SA (1999) Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 274(27):19465–19472

    PubMed  CAS  Google Scholar 

  84. Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y, Sugano S, Akiyama T (2004) DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 23(52):8520–8526

    PubMed  CAS  Google Scholar 

  85. Gonzalez-Sancho JM, Aguilera O, Garcia JM, Pendas-Franco N, Pena C, Cal S, Garcia de Herreros A, Bonilla F, Munoz A (2005) The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene 24(6):1098–1103

    PubMed  CAS  Google Scholar 

  86. Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer CG, Albrecht S, Von Schweinitz D, Pietsch T (2003) Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms’ tumors. Lab Invest 83(3): 429–434

    PubMed  CAS  Google Scholar 

  87. Patil MA, Chua MS, Pan KH, Lin R, Lih CJ, Cheung ST, Ho C, Li R, Fan ST, Cohen SN, Chen X, So S (2005) An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 24(23):3737–3747

    PubMed  CAS  Google Scholar 

  88. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Kondo S, Nakamura Y, Daigo Y (2007) Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 67(6):2517–2525

    PubMed  CAS  Google Scholar 

  89. Boon T, Old LJ (1997) Cancer tumor antigens. Curr Opin Immunol 9(5):681–683

    PubMed  CAS  Google Scholar 

  90. Tammela J, Jungbluth AA, Qian F, Santiago D, Scanlan MJ, Keitz B, Driscoll D, Rodabaugh K, Lele S, Old LJ, Odunsi K (2004) SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immun 4:10

    PubMed  Google Scholar 

  91. de Nooij-van Dalen AG, van Dongen GA, Smeets SJ, Nieuwenhuis EJ, Stigter-van Walsum M, Snow GB, Brakenhoff RH (2003) Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. Int J Cancer 103(6):768–774

    PubMed  Google Scholar 

  92. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y (2007) Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 67(24):11601–11611

    PubMed  CAS  Google Scholar 

  93. Zhang B, Zhang Z, Zhang X, Gao X, Kernstine KH, Zhong L (2012) Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma. Biomarkers 17(4):372–378

    PubMed  CAS  Google Scholar 

  94. Samantaray S, Sharma R, Chattopadhyaya TK, Gupta SD, Ralhan R (2004) Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 130(1):37–44

    PubMed  CAS  Google Scholar 

  95. Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99(2):157–166

    PubMed  CAS  Google Scholar 

  96. Nabeshima K, Inoue T, Shimao Y, Sameshima T (2002) Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52(4):255–264

    PubMed  CAS  Google Scholar 

  97. Wagenaar-Miller RA, Gorden L, Matrisian LM (2004) Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 23(1–2):119–135

    PubMed  CAS  Google Scholar 

  98. de Mingo M, Moran A, Sanchez-Pernaute A, Iniesta P, Diez-Valladares L, Perez-Aguirre E, de Juan C, Garcia-Aranda C, Diaz-Lopez A, Garcia-Botella A, Martin-Antona E, Benito M, Torres A, Balibrea JL (2007) Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology 54(73):315–319

    PubMed  Google Scholar 

  99. Yang X, Staren ED, Howard JM, Iwamura T, Bartsch JE, Appert HE (2001) Invasiveness and MMP expression in pancreatic carcinoma. J Surg Res 98(1):33–39

    PubMed  CAS  Google Scholar 

  100. Ohashi K, Nemoto T, Nakamura K, Nemori R (2000) Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 88(10):2201–2209

    PubMed  CAS  Google Scholar 

  101. Gu ZD, Li JY, Li M, Gu J, Shi XT, Ke Y, Chen KN (2005) Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 100(8):1835–1843

    PubMed  CAS  Google Scholar 

  102. Gu ZD, Chen KN, Li M, Gu J, Li JY (2005) Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma. World J Gastroenterol 11(6):871–874

    PubMed  CAS  Google Scholar 

  103. El-Shahat M, Lotfy M, Fahmy L, Abouel-Nour MF, El-Kenawy Ael M (2004) Prognostic value of microvessel density, matrix metalloproteinase-9 and p53 protein expression in esophageal cancer. J Egypt Natl Canc Inst 16(4):224–230

    PubMed  Google Scholar 

  104. Mroczko B, Kozlowski M, Groblewska M, Lukaszewicz M, Niklinski J, Jelski W, Laudanski J, Chyczewski L, Szmitkowski M (2008) The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta 389(1–2):61–66

    PubMed  CAS  Google Scholar 

  105. Lukaszewicz-Zajac M, Mroczko B, Kozlowski M, Niklinski J, Laudanski J, Szmitkowski M (2009) Elevated levels of serum metalloproteinase 9 in patients with esophageal squamous cell carcinoma. Pol Arch Med Wewn 119(9):558–563

    PubMed  Google Scholar 

  106. Denhardt DT, Lopez CA, Rollo EE, Hwang SM, An XR, Walther SE (1995) Osteopontin-induced modifications of cellular functions. Ann N Y Acad Sci 760:127–142

    PubMed  CAS  Google Scholar 

  107. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10(1 Pt 1):184–190

    PubMed  CAS  Google Scholar 

  108. Ito T, Hashimoto Y, Tanaka E, Kan T, Tsunoda S, Sato F, Higashiyama M, Okumura T, Shimada Y (2006) An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 12(4):1308–1316

    PubMed  CAS  Google Scholar 

  109. Kita Y, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Owaki T, Ishigami S, Aikou T (2006) Expression of osteopontin in oesophageal squamous cell carcinoma. Br J Cancer 95(5):634–638

    PubMed  CAS  Google Scholar 

  110. Wu IC, Wu MT, Chou SH, Yang SF, Goan YG, Lee JM, Chou YP, Bair MJ, Wang TE, Chen A, Chang WH, Kuo FC, Wu DC (2008) Osteopontin expression in squamous cell cancer of the esophagus. World J Surg 32(9):1989–1995

    PubMed  Google Scholar 

  111. Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue H, Kondo M, Mori Y, Tanaka E, Imamura M (2005) Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 68(2–3):285–292

    PubMed  CAS  Google Scholar 

  112. Wu IC, Wu DC, Huang CC, Lin HS, Chen YK, Tsai HJ, Lu CY, Chou SH, Chou YP, Li LH, Tai SY, Wu MT (2010) Plasma decorin predicts the presence of esophageal squamous cell carcinoma. Int J Cancer 127(9):2138–2146

    PubMed  CAS  Google Scholar 

  113. Vestweber D, Kemler R (1984) Some structural and functional aspects of the cell adhesion molecule uvomorulin. Cell Differ 15(2–4):269–273

    PubMed  CAS  Google Scholar 

  114. Nakopoulou L, Zervas A, Gakiopoulou-Givalou H, Constantinides C, Doumanis G, Davaris P, Dimopoulos C (2000) Prognostic value of E-cadherin, beta-catenin, P120ctn in patients with transitional cell bladder cancer. Anticancer Res 20(6B):4571–4578

    PubMed  CAS  Google Scholar 

  115. Sarrio D, Perez-Mies B, Hardisson D, Moreno-Bueno G, Suarez A, Cano A, Martin-Perez J, Gamallo C, Palacios J (2004) Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 23(19): 3272–3283

    PubMed  CAS  Google Scholar 

  116. Ghadimi BM, Behrens J, Hoffmann I, Haensch W, Birchmeier W, Schlag PM (1999) Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling. Eur J Cancer 35(1):60–65

    PubMed  CAS  Google Scholar 

  117. Valizadeh A, Karayiannakis AJ, el-Hariry I, Kmiot W, Pignatelli M (1997) Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120) in colorectal polyps. Am J Pathol 150(6):1977–1984

    PubMed  CAS  Google Scholar 

  118. Chung Y, Lam AK, Luk JM, Law S, Chan KW, Lee PY, Wong J (2007) Altered E-cadherin expression and p120 catenin localization in esophageal squamous cell carcinoma. Ann Surg Oncol 14(11):3260–3267

    PubMed  Google Scholar 

  119. Chan AO, Wong BC, Lan HY, Loke SL, Chan WK, Hui WM, Yuen YH, Ng I, Hou L, Wong WM, Yuen MF, Luk JM, Lam SK (2003) Deregulation of E-cadherin-catenin complex in precancerous lesions of gastric adenocarcinoma. J Gastroenterol Hepatol 18(5):534–539

    PubMed  CAS  Google Scholar 

  120. Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M, Kato I (1994) Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 69(3):580–585

    PubMed  CAS  Google Scholar 

  121. Griffiths TR, Brotherick I, Bishop RI, White MD, McKenna DM, Horne CH, Shenton BK, Neal DE, Mellon JK (1996) Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer 74(4):579–584

    PubMed  CAS  Google Scholar 

  122. Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, Rubin MA, Day ML (2003) The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res 9(17):6447–6452

    PubMed  CAS  Google Scholar 

  123. Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198(1):11–26

    PubMed  CAS  Google Scholar 

  124. Chan AO, Chu KM, Lam SK, Cheung KL, Law S, Kwok KF, Wong WM, Yuen MF, Wong BC (2005) Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer 104(4):740–746

    PubMed  CAS  Google Scholar 

  125. Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, Yuen ST, Law SY, Hui WM, Lai KC, Wong CY, Hu HC, Lai CL, Wong J (2001) Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 48(6):808–811

    PubMed  CAS  Google Scholar 

  126. Chan AO, Chu KM, Lam SK, Wong BC, Kwok KF, Law S, Ko S, Hui WM, Yueng YH, Wong J (2003) Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer. J Clin Oncol 21(12):2288–2293

    PubMed  CAS  Google Scholar 

  127. Chung Y, Law S, Kwong DL, Luk JM (2011) Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus 24(1):49–55

    PubMed  CAS  Google Scholar 

  128. Tammela T, Enholm B, Alitalo K, Paavonen K (2005) The biology of vascular endothelial growth factors. Cardiovasc Res 65(3):550–563

    PubMed  CAS  Google Scholar 

  129. Kitadai Y, Amioka T, Haruma K, Tanaka S, Yoshihara M, Sumii K, Matsutani N, Yasui W, Chayama K (2001) Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 93(5):662–666

    PubMed  CAS  Google Scholar 

  130. Kleespies A, Bruns CJ, Jauch KW (2005) Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie 28(5):281–288

    PubMed  CAS  Google Scholar 

  131. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Banas T (2007) Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett 249(2):171–177

    PubMed  CAS  Google Scholar 

  132. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854

    PubMed  CAS  Google Scholar 

  133. Cho WC (2007) OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 6:60

    PubMed  Google Scholar 

  134. Kim VN, Nam JW (2006) Genomics of microRNA. Trends Genet 22(3):165–173

    PubMed  CAS  Google Scholar 

  135. Shenouda SK, Alahari SK (2009) MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28(3–4):369–378

    PubMed  CAS  Google Scholar 

  136. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2):647–658

    PubMed  CAS  Google Scholar 

  137. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27(15):2128–2136

    PubMed  CAS  Google Scholar 

  138. Zhu S, Si ML, Wu H, Mo YY (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282(19):14328–14336

    PubMed  CAS  Google Scholar 

  139. Luan S, Sun L, Huang F (2010) MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Arch Med Res 41(2):67–74

    PubMed  CAS  Google Scholar 

  140. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP (2009) MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49(5):1571–1582

    PubMed  CAS  Google Scholar 

  141. Lin T, Dong W, Huang J, Pan Q, Fan X, Zhang C, Huang L (2009) MicroRNA-143 as a tumor suppressor for bladder cancer. J Urol 181(3):1372–1380

    PubMed  CAS  Google Scholar 

  142. Lee KH, Chen YL, Yeh SD, Hsiao M, Lin JT, Goan YG, Lu PJ (2009) MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 28(38):3360–3370

    PubMed  CAS  Google Scholar 

  143. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518

    PubMed  CAS  Google Scholar 

  144. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Zen K, Zhang CY (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006

    PubMed  CAS  Google Scholar 

  145. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, Lo YM (2008) Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 54(3):482–490

    PubMed  CAS  Google Scholar 

  146. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E (2010) Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 102(7):1174–1179

    PubMed  CAS  Google Scholar 

  147. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251(3):499–505

    PubMed  Google Scholar 

  148. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 101(32):11755–11760

    PubMed  CAS  Google Scholar 

  149. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58(10):1375–1381

    PubMed  CAS  Google Scholar 

  150. Zhang C, Wang C, Chen X, Yang C, Li K, Wang J, Dai J, Hu Z, Zhou X, Chen L, Zhang Y, Li Y, Qiu H, Xing J, Liang Z, Ren B, Zen K, Zhang CY (2010) Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56(12):1871–1879

    PubMed  CAS  Google Scholar 

  151. Zhang T, Wang Q, Zhao D, Cui Y, Cao B, Guo L, Lu SH (2011) The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond) 121(10):437–447

    CAS  Google Scholar 

  152. Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Morimura R, Nagata H, Kosuga T, Iitaka D, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Otsuji E (2011) Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 105(1): 104–111

    PubMed  CAS  Google Scholar 

  153. Pantel K, Alix-Panabieres C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16(9):398–406

    PubMed  Google Scholar 

  154. Lurje G, Schiesser M, Claudius A, Schneider PM (2010) Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. J Oncol 2010:392652

    PubMed  Google Scholar 

  155. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M (1994) Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 12(4):725–729

    PubMed  CAS  Google Scholar 

  156. Setoyama T, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Ishigami S, Owaki T, Takao S, Aikou T (2006) Carcinoembryonic antigen messenger RNA expression in blood predicts recurrence in esophageal cancer. Clin Cancer Res 12(20 Pt 1):5972–5977

    PubMed  CAS  Google Scholar 

  157. Nakashima S, Natsugoe S, Matsumoto M, Miyazono F, Nakajo A, Uchikura K, Tokuda K, Ishigami S, Baba M, Takao S, Aikou T (2003) Clinical significance of circulating tumor cells in blood by molecular detection and tumor markers in esophageal cancer. Surgery 133(2): 162–169

    PubMed  Google Scholar 

  158. Cao M, Yie SM, Wu SM, Chen S, Lou B, He X, Ye SR, Xie K, Rao L, Gao E, Ye NY (2009) Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis 26(7):751–758

    PubMed  CAS  Google Scholar 

  159. Chiou SK, Jones MK, Tarnawski AS (2003) Survivin—an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 9(4):PI25–PI29

    PubMed  CAS  Google Scholar 

  160. Yin XD, Yuan X, Xue JJ, Wang R, Zhang ZR, Tong JD (2012) Clinical significance of carcinoembryonic antigen-, cytokeratin 19-, or survivin-positive circulating tumor cells in the peripheral blood of esophageal squamous cell carcinoma patients treated with radiotherapy. Dis Esophagus 25(8):750–756

    PubMed  Google Scholar 

  161. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5(11):845–856

    PubMed  CAS  Google Scholar 

  162. Zhang HQ, Wang RB, Yan HJ, Zhao W, Zhu KL, Jiang SM, Hu XG, Yu JM (2012) Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy. Asian Pac J Cancer Prev 13(1):199–203

    PubMed  Google Scholar 

  163. Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ (2000) CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 6(11):4249–4252

    PubMed  CAS  Google Scholar 

  164. Yan HJ, Wang RB, Zhu KL, Jiang SM, Zhao W, Xu XQ, Feng R (2012) Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma. Chin Med J 125(8):1410–1415

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

We would like to acknowledge Dr. Raymond W.Y. Sun for his critical review of the chapter.

Author information

Authors and Affiliations

  1. Department of Surgery, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China

    Kenneth K. Lai, Kin-Tak Chan, Nikki P. Lee & Simon Law

  2. Department of Surgery, The University of Hong Kong, Hong Kong, China

    Sarwat Fatima

  3. School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China

    Sarwat Fatima

Authors
  1. Kenneth K. Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kin-Tak Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarwat Fatima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nikki P. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Simon Law
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simon Law .

Editor information

Editors and Affiliations

  1. Faculty of Medicine Building, Department of Surgery, University of Hong Kong, Sassoon Road 21, Hong Kong, Hong Kong SAR

    Nikki P. Lee

  2. Center for Biomedical Research, Population Council, York Ave. 1230, NEW YORK, 10021, New York, USA

    C.Y. Cheng

  3. Yong Loo Lin School of Medicine, Department of Pharmacology and Departmen, National University of Singapore, Medical Drive 10, Singapore, 117597, Singapore

    John M. Luk

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lai, K.K., Chan, KT., Fatima, S., Lee, N.P., Law, S. (2013). Circulating Biomarkers for Esophageal Squamous Cell Carcinoma. In: Lee, N., Cheng, C., Luk, J. (eds) New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-456-2_6

Download citation

Publish with us

Policies and ethics

Search

Navigation